https://allsci.com/news/pipe-financing/obsidian-til-therapy-melanoma-raises-usd-350m-to/ AllScien 2026-08-03T17:35:22.357246Z Obsidian completes Galera reverse merger and USD 350m PIPE raise https://allsci.com/news/patents-ip/alc1-inhibitors-parp-eisbach-bio-publishes-us-1/ AllScien 2026-08-03T17:32:53.721295Z Eisbach Bio patent application outlines allosteric ALC1 strategy for PARP combinations https://allsci.com/news/clinical-trials/mrna-car-t-hepatocellular-carcinoma-cellorigin/ AllScien 2026-08-03T17:14:51.837933Z CellOrigin advances in vivo mRNA CAR-T for HCC with Walvax partnership https://allsci.com/news/regulatory/fda-fast-track-peanut-allergy-immunotherapy/ AllScien 2026-08-03T16:36:09.988035Z Aravax secures FDA Fast Track designation for PVX108 peanut allergy immunotherapy https://allsci.com/news/funding/annamycin-aml-trial-funding-moleculin-raises-usd/ AllScien 2026-08-03T16:01:35.319797Z Moleculin raises USD 9.3m to fund Annamycin's pivotal AML trial through interim readout https://allsci.com/news/business/supernus-indivior-merger-and-to-build-usd-22/ AllScien 2026-08-03T14:36:27.060202Z Supernus, Indivior agree all-stock merger to create diversified CNS biopharma https://allsci.com/news/regulatory/olomorasib-fda-breakthrough-pancreatic-cancer/ AllScien 2026-08-03T13:56:51.724041Z Lilly's olomorasib earns FDA Breakthrough Therapy designation for KRAS G12C pancreatic cancer https://allsci.com/news/regulatory/ism8969-nmpa-ind-approval-parkinsons-insilico/ AllScien 2026-08-03T12:59:49.582846Z China clears Insilico's BBB-penetrant NLRP3 inhibitor for Parkinson's Phase I study https://allsci.com/news/venture-financing/ratio-therapeutics-series-c-funding-raises-usd/ AllScien 2026-08-03T12:37:25.191866Z Ratio Therapeutics raises USD 70m Series C with Eli Lilly as new strategic investor https://allsci.com/news/debt-financing/annexon-credit-facility-funding-secures-usd-200m/ AllScien 2026-08-03T12:25:53.814058Z Annexon secures USD 200m credit facility as late-stage programs approach market approvals